二甲双胍与利拉鲁肽对青年起病2型糖尿病血糖及糖异生的影响:一项随机试验
该平行随机临床试验纳入22例非洲裔美国青年起病2型糖尿病患者,随机接受二甲双胍单药或二甲双胍联合利拉鲁肽治疗12周。联合治疗组空腹血糖降幅更大、β细胞功能指标sigma升高更明显,但两组糖异生分数变化无差异,且餐后糖异生及全身胰岛素敏感性均无变化。结论认为现有治疗未抑制升高的糖异生。
要点
- 二甲双胍联合利拉鲁肽较单药进一步降低空腹血糖并改善β细胞功能。
- 两方案均未抑制青年起病2型糖尿病患者升高的糖异生。
- 葡萄糖清除率增加与β细胞功能相关,而非糖异生或胰岛素敏感性。
核心结论
- 在青年起病2型糖尿病患者中,二甲双胍联合或不联合利拉鲁肽均改善血糖,但未抑制高糖异生率。
- 需要能增强β细胞功能并靶向升高糖异生率的新型疗法。
研究设计与样本
- 平行随机临床试验,22例青年起病2型糖尿病非洲裔美国患者,年龄15.3±2.1岁,68%女性,BMI 40.1±7.9 kg/m2,诊断病程1.8±1.3年。
- 随机分为二甲双胍单药组或二甲双胍联合利拉鲁肽组,治疗12周,治疗前后评估。
- 采用稳定同位素示踪剂测量过夜空腹及持续进餐期间的糖异生[2H2O]和葡萄糖生成[6,6-2H2]葡萄糖。
- 通过频繁采样的2小时口服葡萄糖耐量试验评估β细胞功能(sigma)和全身胰岛素敏感性(mSI)。
主要发现
- 基线时两组糖异生、葡萄糖生成、空腹及2小时血糖相当,但联合治疗组血红蛋白A1C更高。
- 联合治疗组空腹血糖降幅大于单药组(-2.0±1.3 vs -0.6±0.9 mmol/L,P=0.008),sigma升高幅度更大(0.72±0.68 vs -0.05±0.71,P=0.03)。
- 糖异生分数变化两组相似(联合组:-0.36±9.4 vs 单药组:0.04±12.3%,P=0.9),餐后糖异生及mSI均无变化。
- 两组葡萄糖清除率增加与sigma相关(r=0.63,P=0.003),与糖异生或mSI无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Elevated rates of gluconeogenesis are an early pathogenic feature of youth-onset type 2 diabetes (Y-T2D), but targeted first-line therapies are suboptimal, especially in African American (AA) youth. We evaluated glucose-lowering mechanisms of metformin and liraglutide by measuring rates of gluconeogenesis and β-cell function after therapy in AA Y-T2D. METHODS: In this parallel randomized clinical trial, 22 youth with Y-T2D-age 15.3 ± 2.1 years (mean ± SD), 68% female, body mass index (BMI) 40.1 ± 7.9 kg/m2, duration of diagnosis 1.8 ± 1.3 years-were randomized to metformin alone (Met) or metformin + liraglutide (Lira) (Met + Lira) and evaluated before and after 12 weeks. Stable isotope tracers were used to measure gluconeogenesis [2H2O] and glucose production [6,6-2H2]glucose after an overnight fast and during a continuous meal. β-cell function (sigma) and whole-body insulin sensitivity (mSI) were assessed during a frequently sampled 2-hour oral glucose tolerance test. RESULTS: At baseline, gluconeogenesis, glucose production, and fasting and 2-hour glucose were comparable in both groups, though Met + Lira had higher hemoglobin A1C. Met + Lira had a greater decrease from baseline in fasting glucose (-2.0 ± 1.3 vs -0.6 ± 0.9 mmol/L, P = .008) and a greater increase in sigma (0.72 ± 0.68 vs -0.05 ± 0.71, P = .03). The change in fractional gluconeogenesis was similar between groups (Met + Lira: -0.36 ± 9.4 vs Met: 0.04 ± 12.3%, P = .9), and there were no changes in prandial gluconeogenesis or mSI. Increased glucose clearance in both groups was related to sigma (r = 0.63, P = .003) but not gluconeogenesis or mSI. CONCLUSION: Among Y-T2D, metformin with or without liraglutide improved glycemia but did not suppress high rates of gluconeogenesis. Novel therapies that will enhance β-cell function and target the elevated rates of gluconeogenesis in Y-T2D are needed.
引用
- Dietsche KB, Magge SN, Dixon SA, et al. Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes. J Clin Endocrinol Metab. 2024. PMID: 37967247. doi:10.1210/clinem/dgad669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。